Literature DB >> 21464031

Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

Steven Lipkin1, John Lee, David Imagawa, Stephen M Hewitt, Chris Tucker, Jason A Zell, Vanessa Wong, Angela Garcia, Rachel Gonzalez, Gary Della Zanna, Ellen Richmond, L M Rodriguez, M Bigg, F Schnoll-Sussmans, Frank Meyskens.   

Abstract

Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8). ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21464031      PMCID： PMC4492452          DOI： 10.1158/1940-6207.CAPR-10-0373

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN： 1940-6215


  14 in total

1.  Effects of smoking on the pharmacokinetics of erlotinib.

Authors:  Marta Hamilton; Julie L Wolf; Jason Rusk; Shannon E Beard; Gary M Clark; Karsten Witt; Pablo J Cagnoni
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

2.  Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas.

Authors:  Barbara Chadwick; Carlynn Willmore-Payne; Sheryl Tripp; Lester J Layfield; Sharon Hirschowitz; Joseph Holden
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

3.  Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Suresh T Chari; Dhiraj Yadav; Thomas C Smyrk; Eugene P DiMagno; Laurence J Miller; Massimo Raimondo; Jonathan E Clain; Ian A Norton; Randall K Pearson; Bret T Petersen; Maurits J Wiersema; Michael B Farnell; Michael G Sarr
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

4.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

5.  Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California.

Authors:  Jason A Zell; Jessica M Rhee; Argyrios Ziogas; Steven M Lipkin; Hoda Anton-Culver
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

6.  Pancreatic intraepithelial neoplasia.

Authors:  Kyoichi Takaori; Ralph H Hruban; Anirban Maitra; Nobuhiko Tanigawa
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

Review 7.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

8.  Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells.

Authors:  K Guzman; S H Randell; P Nettesheim
Journal:  Biochem Biophys Res Commun       Date:  1995-12-14       Impact factor: 3.575

9.  Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1.

Authors:  Michaël Perrais; Pascal Pigny; Marie-Christine Copin; Jean-Pierre Aubert; Isabelle Van Seuningen
Journal:  J Biol Chem       Date:  2002-06-19       Impact factor: 5.157

10.  Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.

Authors:  Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969
View more
  1 in total

Review 1.  Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).

Authors:  Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-30       Impact factor: 10.680
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.